

# Chinese Herbal Medicine Treatment for Alzheimer's Disease Inpatients in China: Alternative or Complement to Conventional Medicine, a Cross-sectional Study

Xiaoping Chen<sup>1</sup>, Hao Yan<sup>1</sup>, Stephen Nicholas<sup>3,4,5,6</sup>, Elizabeth Maitland<sup>7</sup>, Zhengwei Huang<sup>1</sup>, Yong Ma<sup>8\*</sup>, and Xuefeng Shi<sup>1,2\*</sup>

\*Correspondence: shixuefeng981206@163.com

<sup>1</sup>School of Management, Beijing University of Chinese Medicine, Beijing, China

<sup>2</sup>National Institute of Traditional Chinese Medicine Strategy and Development, Beijing University of Chinese Medicine, Beijing, China

<sup>3</sup>Australian National Institute of Management and Commerce, Eveleigh Sydney, NSW 2015, Australia

<sup>4</sup>School of Economics and School of Management, Tianjin Normal University, Tianjin, China

<sup>5</sup>Guangdong Institute for International Strategies, Guangdong University of Foreign Studies, Guangzhou, China

<sup>6</sup>Newcastle Business School, University of Newcastle, Newcastle, Callaghan, Australia

<sup>7</sup>School of Management, University of Liverpool, Chatham Building, Chatham Street, Liverpool L697ZH, UK

<sup>8</sup>National Institute of Healthcare Security, Capital Medical University, No.A-28 Fuwai Street, Xicheng District, Beijing, China.

Correspondence should be addressed to Xuefeng Shi, Yong Ma.

## Abstract

**Objectives** Chinese herbal medicine (CHM), a typical type of complementary and alternative medicine (CAM), has been used to treat Alzheimer's disease (AD) with costs covered by China's urban basic medical insurance. Previous studies have demonstrated the treatment effectiveness of CHM for intractable disease and CHM's ability to reduce medical costs. There has been no research exploring the impact of CHM on AD inpatient hospital costs or whether CHM is a complement or alternative to conventional medicine treatments. We compared the medical costs of AD inpatients, CHM users, and non-CHM users to analyze whether CHM has increased or decreased the AD inpatient costs, to assess whether CHM was an alternative or complementary treatment.

**Methods** Our cross-sectional research was based on a 5% random sample from the 2010 to 2016 Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI) claim data, yielding information on 1507 urban AD inpatients. Wilcoxon rank sum test and chi square test were applied to the medical cost data with an abnormal distribution. To control for confounding factors, such as demographic (age and sex) and medical costs, the influence between CHM costs and conventional medicine costs were analyzed by quantile regression.

**Results** CHM users accounted for 79.83% (1203/1507) of the total inpatients. The median inpatient cost of CHM users was RMB13293.95 (USD2084.49), which was higher than non-CHM users' (RMB8428.10/USD1321.53,  $P < 0.001$ ). The median CHM cost was RMB721.00 (USD113.05). Positive correlations between CHM users and CHM costs were found after controlling for confounder variables (Coef.=0.09,  $P < 0.001$ ).

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Conclusion** During 2010-2016, nearly 80% of AD inpatients in our sample used CHM. Participation in CHM increased the total inpatient costs, pharmacy costs, and conventional medicine costs of AD inpatients over non-CHM users. CHM mainly plays a complementary or less alternative role to conventional medicine for AD treatment.

**Key words:** Alzheimer's disease; inpatient costs; CHM; complementary effects

## 1 Background

There are currently over 55 million people worldwide living with dementia, with 60% of people with dementia living in low- and middle-income countries<sup>[1]</sup>. In 2022, the global economic costs of dementia are estimated at USD1.3 trillion<sup>[2]</sup>, with USD167.74 billion dementia costs in mainland China, with 50% of those costs accounted for by hospitalization expenses<sup>[3]</sup>. Alzheimer's disease (AD) is the most common type of dementia, with over 10 million suffering in mainland China. AD is a neurodegenerative disease with cognitive impairment at its core. As AD progresses, and other comorbidities occur, patients experience memory loss, behavioral and psychological symptoms of dementia (including irritability, hallucinations, delusions, or behavior disorders), gradually loss of basic living capacity, which may progress over 10 years from a mild memory loss condition to complete disability<sup>[4,5,6]</sup>. In mainland China, Most AD sufferers are concentrated in the central and eastern regions; the incidence increases exponentially as age increases; and AD as a cause of death rose from the tenth cause in 1990 to fifth in 2019 <sup>[4]</sup>.

AD imposes a heavy economic burden on the patient's families, the hospital system, and the society, which makes an effective treatment desperately needed. Since modern medicine cannot cure AD, experts are increasingly turning to complementary and alternative medicine (CAM) as an AD treatment. Following the U.S. National Center for Complementary and Integrative Health (NCCIH), when CAM is used together with conventional medicine, it is labelled 'complementary' and when it is used in place of conventional medicine, it is an 'alternative'<sup>[7]</sup>. Research on CAM for AD treatment in Japan, Korea, USA, and Canada confirmed the potential anti-inflammatory, memory improving, and neuroprotective effects of CAM<sup>[8]</sup>. Chinese herbal medicine (CHM), a special type of CAM, has been used for AD treatment for hundreds of years in China<sup>[9]</sup>, and CHM treatments are covered by China's basic medical insurance<sup>[10,11][11]</sup>.

CHM's AD treatment is fundamentally different from conventional medicine's therapeutic assumption of promoting cognition from a molecular biology perspective<sup>[12]</sup>. The efficacy of CHM treatment has been shown in clinical trials, where molecular biological experiments have demonstrated neuroprotective and antioxidant effects<sup>[13]</sup>. For example, CHM's GRAPE formula has been found in a retrospective cohort study to complement conventional medicine therapy to delay cognitive impairment in patients with mild to moderate AD, although the efficacy of CHM usually requires long-term continuous treatment<sup>[14]</sup>. Studies in Taiwan, China found that more than 40% of dementia patients used traditional Chinese medicine(TCM), with patients with more comorbidities preferring TCM treatment, and with hospitalization costs lower than non-TCM users <sup>[15,16]</sup>. Ischemic stroke research reported that TCM use increased medical costs, playing a complementary role in treating stroke<sup>[17]</sup>. It remains

inconclusive whether CHM plays a complementary or an alternative role in AD treatment.

Based on the real-world Chinese urban basic medical insurance data, we explore the impact of CHM treatment on AD inpatient costs, especially compared with conventional medicine costs. From a medical treatment cost perspective, we assess whether CHM's AD treatment was a complementary or an alternative to conventional medical treatment.

## 2 Materials and Methods

### 2.1 Data source

Using a 5% random sample from the 2010 to 2016 Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI) claim data, the China Health Insurance Research Association (CHIRA) collected information on 1507 urban AD inpatients. Data comprised demographic information (sex, age), insurance type, settlement type, hospital type, hospital level, length of hospital stay, frequency of hospital visit, diagnosis code, city type, region, year, total inpatient costs, pharmacy costs, CHM costs and conventional medicine costs.

### 2.2 Parameter interpretation

**Insurance type** Urban basic medical insurance was a social medical insurance established by the Chinese government to ease people's medical cost burden. Increasing from 430 million members in 2010 to 740 million in 2016<sup>[18,19]</sup>, China's urban basic medical insurance comprises urban employee basic medical insurance (UEBMI), and urban resident basic medical insurance (URBMI). UEBMI is jointly paid by employees and employers, based on the disposable income of employees. More limited than UEBMI, URBMI covers primary and secondary school students, children, and other nonworking urban residents, with reimbursements related to the resident's disposable income<sup>[20]</sup>. And some provinces have also included the rural population in the basic medical insurance, called Urban and Rural Resident Basic Medical Insurance (URRBMI)<sup>[21-23]</sup>.

**Settlement type** Local settlement, trans-city within province settlement, and trans-provincial settlement are different reimbursement types. Medical insurance payments draw on resources at the provincial, county, and city level, with claimants receiving treatment in the city and province in which they are insured called local settlement; for claimants insured in the province, but not the city, are called trans-city province settlement; and claimants insured in another province are called trans-provincial settlement<sup>[24]</sup>.

**Hospital type** Hospitals are classified into general hospitals, containing specialized units, such as internal medicine, surgery, gynecology, pediatrics; specialized hospitals, providing certain diagnosis and treatment services, such as psychiatric specialties, neurological specialties; traditional Chinese medicine hospitals, providing CHM diagnosis and treatment services; and traditional Chinese medicine-integrated hospital, providing both CHM and conventional medicine diagnosis and treatment services<sup>[25]</sup>.

**Hospital level** There are three levels of hospitals in mainland China, comprising primary, secondary, and tertiary levels, with each level providing a wider range and higher quality of personnel and equipment services, medical training, and medical research to local or provincial patients.

**Diagnosis code** G30, based on the International Statistical Classification of Diseases and Related Health Problems, 10th Edition (ICD-10) was the disease code for AD, with subtypes G30.0 (Alzheimer's disease with early onset, onset usually before the age of 65), G30.1 (Alzheimer's disease with late onset, onset usually after the age of 65), G30.8 (other Alzheimer's disease), and G30.9 (Alzheimer's disease unspecified) [26].

**City type** Based on Chinese 34 provincial-level administrative regions, we classify cities into provincial capital cities, prefecture-level cities, and municipalities directly under the Central Government (Beijing, Tianjin, Shanghai, and Chongqing) [27].

**Region** China divides provincial administrative regions into eastern, central, western, and northeast regions [28]. Eastern region includes Beijing, Tianjin, Hebei, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Guangdong and Hainan. Central region includes Shanxi, Anhui, Jiangxi, Henan, Hubei and Hunan. Western region includes Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Gansu, Qinghai, Ningxia and Xinjiang. Northeast region includes Liaoning, Jilin and Heilongjiang. Because of the small sample size in the northeast region, it was included in the eastern region in this paper.

**Pharmacy costs** all costs related to pharmacy items, including CHM costs and conventional medicine costs.

**Non-pharmacy costs** Such as examination costs, nursing costs, diagnosis costs, testing costs, bed costs, and medical consumables costs, except for medicine (pharmacy) costs.

**CHM and non-CHM users** When AD inpatients' incurred any CHM costs, then the inpatient was a CHM user, otherwise, the inpatient was a non-CHM user.

**CHM** Chinese herbal medicine can be divided into herbal medicine and patent medicine. Herbal medicine is extracted (drying, frying) from plants (ginseng, angelica), animals (tortoise shell, gelatin), minerals (gypsum, calamine). Patent medicine comprises the comprehensive integration of different herbal proportions made into decoctions (*Qi Fu Yin*), tablets (ginkgo leaf pill), or injections (*xueshuantong* injection).

### 2.3 The Sample

The sample comprises 1507 AD hospitalized patients with a discharge time between January 24, 2010 and December 31, 2016. It should be stated in advance that although the medical expenses of all samples are recorded, there are still a small part of missing data. For example, one inpatient's sex, age, and medical expense was recorded in detail, but his settlement type and hospital level were not reported. Therefore, the percentages for many characteristics in Table 1 do not sum to 100%. All costs were based on a the 2013 RMB100=USD15.68 annual average exchange rate.

### 2.4 Statistical analysis

Median and inter-quartile range, M (IQR) were used to describe age, length of hospital stay, frequency of hospital visit, total inpatient costs, non-pharmacy costs, pharmacy costs, conventional medicine costs and CHM costs since the Shapiro-Wilk W test revealed they were not normally distributed ( $P<0.001$ ). Numbers of AD inpatients and proportion of cases were described by cases (n) and proportion (%). The distribution of AD cases between CHM users and non-CHM users were examined by the chi square test and Two-sample Wilcoxon rank sum test, and the differences of age, length of hospital stay, frequency of hospital visit, and costs between CHM users and non-CHM users were analyzed by Two-sample Wilcoxon rank sum test. To quantify the impact of CHM use on total inpatient costs, and the relationship between CHM costs and conventional medicine costs, quantile regression analysis, adjusting for confounding factors, was used.  $P<0.05$  was statistically significant. The statistical processing software was Stata/MP 16.0.

## 2.5 Patient and public involvement

None

## 3 Results

### 3.1 Basics Characteristics

As shown in Table 1, 79.83% (1203/1507) of the 1507 AD inpatients were CHM users, and 20.17% (304/1507) were non-CHM users. The median age was 80 years old, with no statistically significant ( $P>0.05$ ) between the age of CHM users and non-CHM users, but the age distribution was significant different ( $P<0.05$ ) between CHM users and non-CHM users. Eighty-seven percent (1315/1507) of AD inpatients were in the UEBMI group, and 70.74% of UEBMI insured were CHM users. There were 72.33% (1090/1507) local settlement inpatients. Only 3.52% (53/1507) of the inpatients were treated at CHM hospital. Most inpatients (90.25%) only visited the hospital once, with CHM users statistically more likely to visit the hospital only once compared to non-CHM users' ( $P<0.05$ ). On a regional basis, 67.75% ( $P<0.05$ ) of CHM users came from the west region and central region, which was statistically higher than non-CHM cases. More than half cases (62.31%) of CHM users were treated during the 2014 to 2016 year. Any difference in the distribution of cases among sex, length of hospital stay, diagnosis type, and city type between CHM users and non-CHM users was not statistically significant ( $P>0.05$ ).

### 3.2 Total Inpatient Costs between CHM Users and non-CHM Users

Table 2 shows the cost difference in CHM users and non-CHM users. The median total inpatient cost for CHM users was RMB13293.95/USD2084.49, significantly higher than non-CHM users (RMB8428.10/USD1321.53,  $P<0.001$ ). Across sex, age (except 80-85 years old), insurance type, settlement type (local), hospital type (general, specialized), hospital level (secondary, tertiary), frequency of hospital visit (once, 1~6th), length of hospital stay, diagnosis type (G30.9), city type, region, year (2013, 2014, 2015, 2016), CHM users' total inpatient costs were statistically significant higher than non-CHM users' ( $P<0.05$ ).

### **3.3 Quantile Regression Analysis of Total Inpatient Costs between CHM Users and non-CHM Users**

To further analyze the differences in total inpatient costs between CHM users and non-CHM users, we used a quantile regression analysis and included statistically significant factors in Table 2 as confounders. As shown in Table 3, CHM users' inpatient costs were RMB6898.29/USD1081.65 higher than non-CHM users' (Coef.=6898.29,  $P < 0.001$ ,  $R^2 = 0.2133$ ), with confounders (sex, age group, insurance type, settlement type, hospital type, hospital level, frequency of hospital visit, length of hospital stay, type of diagnosis, type of city, region, year) fixed.

### **3.4 Composition of Total Inpatient Costs between CHM Users and non-CHM users**

As shown in Table 4, we compared the inpatient cost components between CHM users and non-CHM users, which explained why total inpatient costs were higher in CHM users'. We separated the total inpatient costs into pharmacy costs and non-pharmacy costs for conventional medicine treatment and CHM treatment. Two-sample Wilcoxon rank sum test showed that non-pharmacy costs, pharmacy costs, and conventional medicine costs of CHM users were significantly higher than those of non-CHM users' ( $P < 0.001$ ).

### **3.5 Quartile Regression Analysis of CHM Costs**

Table 4 shows that CHM treatment had an important impact on pharmacy costs. We conducted a quantile regression on the relationship between conventional medicine costs and CHM costs, adjusted for the impact of confounders (hospital type, hospital level, frequency of hospital visit, length of hospital stay, type of diagnosis, type of city, region, year). As shown in Table 5, conventional medicine costs had a positive impact on CHM costs. When confounders remain unchanged, for every RMB1/USD0.16 increase of conventional medicine costs, CHM costs increased by RMB0.09/USD0.01 (Coef.=0.09,  $P < 0.001$ ,  $R^2 = 0.1998$ ). CHM costs increased with the costs of conventional medicine, indicating that CHM played a complementary role to conventional medicine instead of an alternative treatment role replacing conventional medicine for AD inpatients.

#### 4 Discussion

CHM is a special type of CAM, and whether CHM is an alternative or complement to conventional medicine remains controversial. Ruling that the effectiveness of herb medicine was based on traditional use rather than scientific research, the UK's National Health Service medication guidelines do not recommend CHM as supplements to other drugs<sup>[29]</sup>. In contrast, the U.S. National Center for Complementary and Integrative Health regards herbs as a type of complementary health approach<sup>[7]</sup>. The Chinese government advocates equal emphasis on CHM and conventional medicine and promotes the mutual complement and coordinated development of both<sup>[30]</sup>. One approach to explaining whether CHM is a complementary or an alternative treatment process to conventional medicine is from the perspective of medical expenses. Research based on National Health Insurance (NHI) in Taiwan, China has shown that medical costs for uterine fibroid patients with Chinese medicine therapy were lower than Chinese medicine nonusers, and concluded that Chinese medicine was an alternative therapy to conventional medicine<sup>[31]</sup>. Evidence from mainland China found that the inpatient stroke costs of TCM users were higher than those of TCM nonusers, concluding that TCM was a complementary treatment to conventional medicine<sup>[17]</sup>. Based on 2010-2016 cross-sectional urban basic medical insurance inpatient cost data in mainland China, we explored whether CHM treatment of AD was an alternative or complement to conventional medical treatment. Compared with non-CHM users (20.17%), 79.83% of AD inpatients received CHM treatment. Two-sample Wilcoxon rank sum test for costs revealed that the non-pharmacy costs, pharmacy costs, and conventional medicine costs of CHM users were statistically significantly higher than those of non-CHM users. As shown in the quantile regression of the relationship between conventional medicine costs and CHM costs, which was adjusted for confounders (including hospital type, hospital level, frequency of hospital visit, length of hospital stay, diagnosis type, city type, region, year), CHM costs increased with rising conventional medicine costs. CHM treatment neither reduced non-pharmacy costs nor pharmacy costs, but acted as additional treatment cost. We conclude that CHM was a complementary therapy rather than an alternative for AD hospitalization treatment.

We suggest that the following reasons help explain the complementary role of CHM in AD treatment. First, conventional medicine dominates the medical market in mainland China. Although China has been exploring CHM treatments for AD for many years, it was not until 2018 that standardized CHM clinical pathways for AD were formally determined<sup>[32,33]</sup>. In contrast, conventional medicine treatments, such as donepezil and rivastigmine, have been used in medical institutions as anti-AD drugs since 2009<sup>[10]</sup>. Second, some research has shown that the combination of CHM and conventional medicine can produce better effects than monotherapy. Different from the precise positioning of disease etiology, pathology, and anatomy of conventional medicine, CHM paid attention to the human body and nature environment from a systemic perspective. The combination therapy of CHM and conventional medicine can treat AD from two different perspectives, macroscopic and microscopic, and the effect will definitely be better<sup>[12,14]</sup>. Third, the profits of drug mark-ups affected doctors'

prescription behavior. Before 2017, several provinces in mainland China implemented a drug mark-up policy, where medicine sold by the hospital was priced higher than the market retail price, providing a profit-making income for the hospital<sup>[34]</sup>. Finally, the best integrated clinic pathways between conventional medicine and CHM has not been found. To realize the best practice of CHM and conventional medicine, the Chinese government plans to train high-level integrated CHM and conventional medicine experts and general practitioners over the next 10-15 years<sup>[35]</sup>.

## 5 Conclusion

In mainland China, approximately 80% of patients with AD were CHM users. Participation in CHM AD treatment increased the total inpatient costs, pharmacy costs, and conventional medicine costs of AD inpatients over non-CHM users. CHM mainly plays a complementary or less alternative role to conventional medicine for AD treatment.

## Strengths and Limitations

This study has some limitations. Our data were stratified sample from urban basic medical insurance in mainland China with a sampling frequency of one year and one time, which can only sample sectional inpatient costs for AD among its decades disease progression. Furthermore, the severity and comorbidity of AD were important indicators affecting inpatient costs, but these data were not available in our database. Acupuncture and moxibustion were essential non-pharmacy TCM therapies for AD, but data on such treatments were not available. Finally, our data were from 2010 to 2016, but in 2017, the Chinese government proposed a new policy to further promote TCM development, which might influence our conclusions.

## Abbreviations

AD: Alzheimer's Disease

TCM: Traditional Chinese medicine

CHM: Chinese herbal medicine

UEBMI: Urban Employee Basic Medical Insurance

URBMI: Urban Resident Basic Medical Insurance

URRBMI: Urban and Rural Resident Basic Medical Insurance

IQR: Inter-quartile range

## Declarations

### ● Ethics approval and consent to participate

Since the claim data the authors used were an anonymized and secondary database, human participants are not directly involved in the study. The Ethics Committee of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (no.2019BZHYLL0201) has waived the subsequent ethical application and informed consent application.

### ● Consent for publication

Not Applicable.



- **Availability of data and materials**

The data that support the findings of this study are available from China Health Insurance Research Association, but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are however available from Xuefeng Shi upon reasonable request and with permission of the China Health Insurance Research Association.

If someone wants to request the data from this study, please contact the China Health Insurance Research Association.

- **Competing Interests**

The authors stated that they have no conflicts of interest which might be perceived as posing a conflict or bias.

- **Funding statement**

This work was supported by the Research on the implementation strategy of traditional Chinese medicine disease classification and payment [grant number: 90020671720021].

- **Authors' Contributions**

Xiaoping Chen and Hao Yan developed the research aims, drafted the manuscript, and analyzed the data; Xuefeng Shi, Stephen Nicholas, and Elizabeth Maitland revised the manuscript; Xuefeng Shi and Yong Ma developed the research idea; Yong Ma and Zhengwei Huang oversaw the data collection; Xuefeng Shi collected the data and helped develop the idea and edited the manuscript. All authors reviewed the manuscript.

- **Acknowledgments**

The authors acknowledge the China Health Insurance Research Association for providing access to their claims data.

## Reference

- [1] World Health Organization. Dementia.[EB/OL]. (2021-09-02) [2022-01-15].<https://www.who.int/news-room/fact-sheets/detail/dementia>.
- [2] Alzheimer's Disease International (ADI) . Dementia facts & figures.[2022-01-15]. <https://www.alzint.org/about/dementia-facts-figures/>.
- [3] Jian ping J,Cuibai W,Shuoqi C,et al.The cost of Alzheimer's disease in China and re-estimation of costs worldwide[J].Alzheimer's & Dementia: The Journal of the Alzheimer's Association,2018,14(4).
- [4] Kolanowski A, Boltz M, Galik E, Gitlin LN, Kales HC, Resnick B, Van Haitsma KS, Knehans A, Sutterlin JE, Sefcik JS, Liu W, Petrovsky DV, Massimo L, Gilmore-Bykovskiy A, MacAndrew M, Brewster G, Nalls V, Jao YL, Duffort N, Scerpella D. Determinants of behavioral and psychological symptoms of dementia: A scoping review of the evidence. *Nurs Outlook*. 2017 Sep-Oct;65(5):515-529. doi: 10.1016/j.outlook.2017.06.006. Epub 2017 Jun 16. PMID: 28826872; PMCID: PMC6579119.
- [5] Tian Jinzhou. Chinese guidelines for the diagnosis and treatment of Alzheimer's disease and other dementia [M]. People's Medical Publishing House, 2017:279.
- [6] Ren Rujing, Yin Peng, Wang Zhihui, etc. 2021 Alzheimer's Disease Report in China[J]. *Journal of Diagnostics Concepts & Practice*, 2021,20 (04): 317-337.
- [7] Complementary, Alternative, or Integrative Health: What's In a Name?[EB/OL]. (2021-04)[2022-01-15].<https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name>.
- [8] Cooper EL, Ma MJ.Alzheimer Disease: Clues from traditional and complementary medicine.J Tradit Complement Med.2017 Jan 16;7(4):380-385. doi: 10.1016/j.jtcme.2016.12.003. PMID: 29034183; PMCID: PMC5634730.
- [9] Zhang J.Jing Yue Quan Shu.Shanghai: Shanghai Scientific & Technical Publishers; 1996:576.
- [10] Written by the Ministry of Human Resources and Social Security of the People's Republic of China. National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue 2009 Edition [M].Beijing: China Human Resources & Social Security Publishing Group, 2009.12:51,108-174.
- [11] Notice of the National Healthcare Security Administration, the Ministry of Human Resources and Social Security of the People's Republic of China on the Issuance of the Drug Catalogue of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2021)\_Medical Administration\_China Government Network.[EB/OL]. (2021-12-03) [2022-01-15]. [http://www.gov.cn/zhengce/zhengceku/2021-12/03/content\\_5655651.htm](http://www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm)
- [12] Lu AP, Jia HW, Xiao C,et al.Theory of traditional Chinese medicine and therapeutic method of diseases.*World J Gastroenterol*.2004 Jul 1;10(13):1854-6.
- [13] Singh SK, Srivastav S, Castellani RJ,et al.Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. *Neurotherapeutics*.2019 Jul;16(3):666-674.
- [14] Shi J, Ni J, Lu T, Zhang X, Wei M, Li T, Liu W, Wang Y, Shi Y, Tian J.Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to

- patients with Alzheimer's disease: a retrospective analysis. *BMC Complement Altern Med.* 2017 Dec 13;17(1):533. doi: 10.1186/s12906-017-2040-5. PMID: 29237450; PMCID: PMC5729264.
- [15] Lin SK, Tsai YT, Lai JN, Wu CT. Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: a nationwide database study. *J Ethnopharmacol.* 2015 Feb 23;161:108-15. doi: 10.1016/j.jep.2014.12.015. Epub 2014 Dec 17. PMID: 25527314.
- [16] Lin SK, Lo PC, Chen WC, Lai JN. Integrating traditional Chinese medicine healthcare into dementia care plan by reducing the need for special nursing care and medical expenses. *Medicine (Baltimore).* 2019 Feb;98(7):e14468. doi: 10.1097/MD.00000000000014468. PMID: 30762764; PMCID: PMC6407982.
- [17] Huang Z, Shi X, Nicholas S, Maitland E, Yang Y, Zhao W, Ma Y, Jiang Y. Use of Traditional Chinese Medicine and Its Impact on Medical Cost among Urban Ischemic Stroke Inpatients in China: A National Cross-Sectional Study. *Evid Based Complement Alternat Med.* 2021 Oct 29;2021:8554829. doi: 10.1155/2021/8554829. PMID: 34745303; PMCID: PMC8570870.
- [18] The Human Resource and Social Security Career Development Statistical Bulletin of 2010. [EB/OL]. (2011-07-20) [2022-01-15]. [http://www.mohrss.gov.cn/SYrlzyhshbzb/zwgk/szrs/tjgb/201107/t20110720\\_69907.html](http://www.mohrss.gov.cn/SYrlzyhshbzb/zwgk/szrs/tjgb/201107/t20110720_69907.html).
- [19] The Human Resource and Social Security Career Development Statistical Bulletin of 2016. [EB/OL]. (2018-05-21) [2022-01-15]. [http://www.mohrss.gov.cn/SYrlzyhshbzb/zwgk/szrs/tjgb/201805/t20180521\\_294286.html](http://www.mohrss.gov.cn/SYrlzyhshbzb/zwgk/szrs/tjgb/201805/t20180521_294286.html).
- [20] Yang Y, Nicholas S, Li S, et al. Health care utilization for patients with stroke: a 3-year cross-sectional study of China's two urban health insurance schemes across four cities. *BMC Public Health.* 2021 Mar 18;21(1):531. doi: 10.1186/s12889-021-10456-x. PMID: 33736618; PMCID: PMC7977157.
- [21] People's Government of Guangdong Province. Forward the Notifications of The State Council on Integrating the Basic Medical Insurance System for Urban and Rural Residents. [EB/OL]. (2016-05-18) [2023-04-05]. [http://www.gd.gov.cn/gkmlpt/content/0/144/post\\_144903.html#7](http://www.gd.gov.cn/gkmlpt/content/0/144/post_144903.html#7).
- [22] People's Government of Chengdu City. Interim Measures of Chengdu City for Basic Medical Insurance for Urban and Rural Residents. [EB/OL]. (2008-11-18) [2023-04-05]. [http://cdhrss.chengdu.gov.cn/cdrs/c109727/2017-11/29/content\\_0fccb3ae3c874aa9874b7ce6e7d5f4e1.shtml](http://cdhrss.chengdu.gov.cn/cdrs/c109727/2017-11/29/content_0fccb3ae3c874aa9874b7ce6e7d5f4e1.shtml).
- [23] People's Government of Changsha City. Notice on Issuing Measures of Basic Medical Insurance for Urban and Rural Residents of Changsha City. [EB/OL]. (2011-03-07) [2023-04-05]. [http://www.changsha.gov.cn/zfxxgk/zfwjk/szfbgt/201103/t20110307\\_82407.html](http://www.changsha.gov.cn/zfxxgk/zfwjk/szfbgt/201103/t20110307_82407.html).
- [24] Li L, Zhou Q, Yin T, Ji Z, Zhang L. Does the Direct Settlement Policy of Trans-Provincial Outpatient Expenses Aggravate the Siphoning Effect? An Empirical Study on Yangtze River Delta, China. *Int J Environ Res Public Health.* 2021 Sep

- 23;18(19):10001. doi: 10.3390/ijerph181910001. PMID: 34639302; PMCID: PMC8507957.
- [25] Notice of Issuing on the Basic Standards of Medical Institutions(Trial).[EB/OL].[2022-01-15].<http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=4d84820f321144c290ddaacba53cb590>.
- [26] Dong Jingwu's main translation. The International Statistical Classification of Diseases and Related Health Problems 10th Revision, Edition 2, Volume 1 [M].Beijing: People's Medical Publishing House, No.06:326,2008.
- [27] Ministry of Civil Affairs of the People's Republic of China.National Administrative Division Information Query Platform.[EB/OL].[2022-01-15].<http://xzqh.mca.gov.cn/map>.
- [28] National Bureau of Statistics. How are economic zones divided? [EB/OL]. (2022-02-21)[2023-04-05].[http://www.stats.gov.cn/hd/cjwtd/202302/t20230207\\_1902279.html](http://www.stats.gov.cn/hd/cjwtd/202302/t20230207_1902279.html).
- [29] National Health Service. Herbal medicine.[EB/OL].(2021-11-23) [2022-01-15].<https://www.nhs.uk/conditions/herbal-medicines/>.
- [30] National Administration of Traditional Chinese Medicine. Open a new era of traditional Chinese medicine inheritance and development.[EB/OL].(2021-06-29) [2022-01-15].<http://www.satcm.gov.cn/xinxifabu/meitibaodao/2021-06-29/22153.html>.
- [31] Su SY, Muo CH, Morisky DE. Use of Chinese medicine correlates negatively with the consumption of conventional medicine and medical cost in patients with uterine fibroids: a population-based retrospective cohort study in Taiwan. BMC Complement Altern Med. 2015 Apr 23;15:129. doi: 10.1186/s12906-015-0645-0. PMID: 25902837; PMCID: PMC4414285.
- [32] Blockbuster!The clinical path and TCM diagnosis and treatment plan of 95 TCM dominant diseases (2018 edition) were released on the government website of the National Administration of Traditional Chinese Medicine.[EB/OL].(2019-01-25)[2022-01-15].  
<http://www.satcm.gov.cn/hudongjiaoliu/guanfangweixin/2019-01-25/8909.html>.
- [33] China Association of Chinese Medicine.[EB/OL].(2018-11-30) [2022-01-15].  
<http://www.cacm.org.cn/zhzyyxh/tzgg/lanmutzgg.shtml>.
- [34] Meng Q, Mills A, Wang L, Han Q.What can we learn from China's health system reform? BMJ.2019 Jun 19;365:l2349. doi: 10.1136/bmj.l2349. PMID: 31217222; PMCID: PMC6598719.
- [35] General Office of the State Council of the People's Republic of China issuing a notice on several policies and measures to accelerate the development of traditional Chinese medicine characteristics. Published by National Administration of Traditional Chinese Medicine official website(satcm.gov.cn).[EB/OL].(2021-02-09)[2022-01-15].  
<http://www.satcm.gov.cn/xinxifabu/guowuyuanxinxi/2021-02-09/20093.html>.

Table 1 Sample characteristics of CHM users and non-CHM users among AD Inpatients

Characteristics		Overall		CHM users		non-CHM users		P
		Cases	Percentage	Cases	Percentage	Cases	Percentage	
Total		1507	100.00%	1203	79.83%	304	20.17%	
Sex	Male	628	41.67%	497	32.98%	131	8.69%	0.589
	Female	877	58.20%	704	46.72%	173	11.48%	
Age (years), M (IQR)		80	73~84	80	73~84	78	70~85	0.123
Age group(years)	<65	151	10.02%	97	6.44%	54	3.58%	0.033
	65~70	130	8.63%	113	7.50%	17	1.13%	
	70~75	172	11.41%	125	8.29%	47	3.12%	
	75~80	273	18.12%	226	15.00%	47	3.12%	
	80~ 85	432	28.67%	371	24.62%	61	4.05%	
	≥85	329	21.83%	253	16.79%	76	5.04%	
Insurance type	UEBMI	1315	87.26%	1066	70.74%	249	16.52%	0.002
	URBMI	192	12.74%	137	9.09%	55	3.65%	
Settlement type	Local	1090	72.33%	867	57.53%	223	14.80%	0.043
	Trans-city within province	123	8.16%	87	5.77%	36	2.39%	
	Trans-provincial	36	2.39%	31	2.06%	5	0.33%	
Hospital type	General	566	37.56%	458	30.39%	108	7.17%	0.001
	Specialized	616	40.88%	486	32.25%	130	8.63%	
	Traditional Chinese medicine	53	3.52%	52	3.45%	1	0.07%	
	Traditional Chinese medicine-integrated	51	3.38%	48	3.19%	3	0.20%	
Hospital level	Primary	267	17.72%	187	12.41%	80	5.31%	<0.001
	Secondary	498	33.05%	428	28.40%	70	4.64%	
	Tertiary	700	46.45%	561	37.23%	139	9.22%	
Frequency of hospital visit (times), M (IQR)		1	1~1	1	1~1	1	1~1	0.005

Characteristics		Overall		CHM users		non-CHM users		P
		Cases	Percentage	Cases	Percentage	Cases	Percentage	
Frequency of hospital visit (times)	once	1360	90.25%	1099	72.93%	261	17.32%	0.004
	1~6th	108	7.17%	69	4.58%	39	2.59%	
	More than 6th	32	2.12%	29	1.92%	3	0.20%	
Length of hospital stay (days), M (IQR)		20	5~53	20	6~47	20	3~81	0.541
Length of hospital stay (days)	≤30	931	61.78%	744	49.37%	187	12.41%	0.060
	30~60	213	14.13%	191	12.67%	22	1.46%	
	60~90	187	12.41%	135	8.96%	52	3.45%	
	>90	152	10.09%	111	7.37%	41	2.72%	
Diagnosis code	G30.0	51	3.38%	38	2.52%	13	0.86%	0.107
	G30.1	96	6.37%	82	5.44%	14	0.93%	
	G30.8	6	0.40%	3	0.20%	3	0.20%	
	G30.9	1305	86.60%	1044	69.28%	261	17.32%	
City type	Provincial capital	336	22.30%	281	18.65%	55	3.65%	0.114
	Municipality	384	25.48%	298	19.77%	86	5.71%	
	Prefecture-level city	787	52.22%	624	41.41%	163	10.82%	
Region	East	208	13.80%	182	12.08%	26	1.73%	<0.001
	West	509	33.78%	351	23.29%	158	10.48%	
	Central	790	52.42%	670	44.46%	120	7.96%	
Year	2010	34	2.26%	29	1.92%	5	0.33%	<0.001
	2011	36	2.39%	29	1.92%	7	0.46%	
	2012	44	2.92%	38	2.52%	6	0.40%	
	2013	170	11.28%	146	9.69%	24	1.59%	
	2014	338	22.43%	288	19.11%	50	3.32%	
	2015	327	21.70%	261	17.32%	66	4.38%	
	2016	534	35.43%	390	25.88%	144	9.56%	

Note: Percentage = Cases/1507×100%. P-values of frequency of hospital visit, length of hospital stay between CHM users and non-CHM users were based on Two-sample Wilcoxon rank sum test. CHM: Chinese herbal medicine; UEBMI: Urban Employee Basic Medical Insurance; URBMI: Urban Resident Basic Medical Insurance; IQR: Inter-quartile range.

Table 2 Total Inpatient Costs between CHM Users and non-CHM Users

Characteristics	CHM users		non-CHM users		P	
	Median	IQR	Median	IQR		
Total	13293.95	15553.98	8428.10	13047.98	<0.001	
Sex	Male	13439.71	18749.35	8750.12	14713.82	<0.001
	Female	13236.00	14333.16	7937.56	12525.16	<0.001
Age group (years)	<65	10635.75	13388.67	5619.07	7152.75	<0.001
	65~70	10616.76	10577.84	2972.29	2379.19	<0.001
	70~75	11005.34	12880.87	6480.68	7306.58	0.001
	75~80	12217.83	17030.15	5398.25	8942.95	<0.001
	80~ 85	14492.16	14862.61	14571.62	11716.82	0.317
	≥85	17795.42	19867.48	16218.78	14352.29	0.002
Insurance type	UEBMI	14397.64	15478.46	10240.23	13578.80	<0.001
	URBMI	6416.00	10616.53	4473.03	9240.95	0.003
Settlement type	Local	14947.07	16576.41	10178.50	13719.26	<0.001
	Trans-city within province	7568.80	8948.91	9864.03	14854.69	0.501
	Trans-provincial	13711.02	12134.01	13476.67	8891.01	0.225
Hospital type	General	12288.69	14080.67	5830.39	7042.11	<0.001
	Specialized	14857.10	15266.65	14992.98	14013.75	0.005
	Traditional Chinese medicine	10029.48	10338.31	5224.64	0.00	0.214
	Traditional Chinese medicine-integrated	25406.79	16907.07	11132.43	21388.34	0.150
Hospital level	Primary	17720.35	15836.53	16848.45	7850.39	0.184

Characteristics	CHM users		non-CHM users		P	
	Median	IQR	Median	IQR		
Frequency of hospital visit (times)	Secondary	10121.71	13808.78	4532.78	4415.01	<0.001
	Tertiary	14759.23	16889.73	7000.08	10555.11	<0.001
	once	12945.08	15224.05	9373.14	13569.75	<0.001
	1~6th	13140.73	17313.31	6802.53	8044.00	0.001
	More than 6th	27922.72	20050.24	2972.17	31442.18	0.118
Length of hospital stay (days)	≤30	10443.31	11925.71	5539.99	8530.96	<0.001
	30~60	16546.88	12857.69	4233.89	2693.53	<0.001
	60~90	22749.50	21057.91	13964.97	7430.96	0.001
	>90	23874.10	16198.76	17781.40	6446.19	<0.001
Diagnosis code	G30.0	8252.11	7172.18	6384.33	9736.50	0.589
	G30.1	10211.06	8340.11	7167.70	21208.40	0.442
	G30.8	11903.16	120000.0	6406.14	24115.73	0.275
	G30.9	14486.65	16467.69	9534.51	13059.14	<0.001
City type	Provincial capital	12189.58	13412.37	7629.49	12922.06	<0.001
	Municipality	17834.75	16825.89	12963.44	15324.92	0.001
	Prefecture-level city	12549.21	19335.47	5773.92	10770.87	<0.001
Region	East	15346.99	16518.94	6957.58	10450.76	<0.001
	West	11176.22	12421.27	10992.50	14316.78	0.008
	Central	10742.97	16841.63	6058.63	10445.32	0.005
Year	2010	11765.50	11052.95	6802.53	1329.35	0.056
	2011	9966.08	14706.91	3523.95	1520.91	0.082
	2012	11434.47	13627.40	7720.74	10545.43	0.259
	2013	10062.22	11817.87	4301.12	6596.00	<0.001
	2014	14828.81	14810.53	10755.97	16680.71	0.010
	2015	12579.92	14376.04	8819.55	16749.85	0.004
	2016	15901.99	18420.00	10827.73	12650.86	<0.001



Note: P values were based on the Two-sample Wilcoxon rank sum test; CHM: Chinese herbal medicine; UEBMI: Urban Employee Basic Medical Insurance; URBMI: Urban Resident Basic Medical Insurance; IQR: Inter-quartile range.

Table 3 Quantile Regression Analysis of Total Inpatient Costs

Characteristics		Coef.	Std.Err.	t	P>t	[95% Conf. Interval]	
Use of CHM (non-CHM users for reference)	CHM-users	6898.29	1155.914	5.97	0.000	4626.306	9170.284
Sex (Male for reference)	Female	1069.79	870.807	1.23	0.220	-641.806	2781.396
Age group (years) (<65 for reference)	65~70	-357.67	1514.646	-0.24	0.813	-3334.760	2619.420
	70~75	1303.02	1476.872	0.88	0.378	-1599.820	4205.870
	75~80	1890.44	1297.271	1.46	0.146	-659.392	4440.272
	≥85	2226.26	1388.019	1.60	0.109	-501.940	4954.460
Insurance type (URBMI for reference)	UEBMI	4393.29	1273.408	3.45	0.001	1890.362	6896.218
Hospital type (Specialized for reference)	General	-3571.78	976.320	-3.66	0.000	-5490.777	-1652.793
Hospital level (Secondary for reference)	Tertiary	2105.62	952.754	2.21	0.028	232.949	3978.291
Frequency of hospital visit (times) (Once for reference)	1~6th	2383.11	1536.195	1.55	0.122	-636.336	5402.556
Length of hospital stay (days) (≤30 for reference)	30~60	4876.86	1300.766	3.75	0.000	2320.159	7433.561
	60~90	19573.25	1794.292	10.91	0.000	16046.510	23100.000
	>90	11781.19	1537.534	7.66	0.000	8759.113	14803.270
City type (Prefecture-level city for reference)	Provincial capital	-1047.54	1140.282	-0.92	0.359	-3288.805	1193.725
	Municipality	6311.99	1266.385	4.98	0.000	3822.871	8801.119
Region (Central for reference)	West	-637.17	1189.901	-0.54	0.593	-2975.963	1701.623
	East	-3147.76	1524.595	-2.06	0.040	-6144.410	-151.120

Characteristics		Coef.	Std.Err.	t	P>t	[95% Conf. Interval]	
Year (2013 for reference)	2014	-814.555	1823.538	-0.45	0.655	-4398.783	2769.673
	2015	-2833.69	1813.871	-1.56	0.119	-6398.918	731.538
	2016	-365.09	1770.854	-0.21	0.837	-3845.766	3115.586
_cons		1090.08	2548.714	0.43	0.669	-3919.507	6099.667

Note:  $R^2 = 0.2133$  in a quantile regression model that was adjusted for use of CHM, sex, age group, insurance type, hospital type, hospital level, frequency of hospital visit, length of hospital stay, city type, region, year. baseline represents the inpatient cost for a 60 to 65 years old male who did not use any CHM with Urban Resident Basic Medical Insurance admitted to a specialized and secondary hospital only once within 30 days' hospital stay in the prefecture-level and central region city in the year of 2013. CHM: Chinese herbal medicine; UEBMI: Urban Employee Basic Medical Insurance; URBMI: Urban Resident Basic Medical Insurance.

Table 4 Composition of Total Inpatient Costs between CHM Users and non-CHM Users

Characteristics	CHM users		non-CHM users		P
	Median	IQR	Median	IQR	
Total inpatient costs	13293.95	15553.98	8428.11	13047.98	<0.001
Non-pharmacy costs	9136.87	12093.69	5856.95	13411.22	<0.001
Pharmacy costs	2947.97	5416.78	672.77	2012.79	<0.001
Conventional medicine costs	2040.28	4263.67	672.77	2012.79	<0.001
CHM costs	721.00	1363.92	--	--	--

Note: P values were based on the Two-sample Wilcoxon rank sum test. CHM: Chinese herbal medicine; UEBMI: Urban Employee Basic Medical Insurance; URBMI: Urban Resident Basic Medical Insurance; IQR: Inter-quartile range.

Table 5 Quartile Regression Analysis of CHM Costs

Characteristics		Coef.	Std.Err.	t	P>t	[95% Conf. Interval]	
Conventional medicine costs		0.090	0.008	11.80	0.000	0.075	0.105
Sex (Male for reference)	Female	46.158	84.631	0.55	0.586	-119.963	212.279
Age group (years)	65~70	276.668	192.946	1.43	0.152	-102.061	655.398

Characteristics		Coef.	Std.Err.	t	P>t	[95% Conf. Interval]	
(<65 for reference)	70~75	-28.490	190.447	-0.15	0.881	-402.315	345.335
	75~80	93.168	169.604	0.55	0.583	-239.745	426.080
	80~85	129.790	162.452	0.80	0.425	-189.084	448.664
	≥85	66.652	170.827	0.39	0.697	-268.661	401.964
Insurance type	UEBMI	31.642	139.064	0.23	0.820	-241.323	304.607
(URBMI for reference)							
Settlement type (Trans-provincial or reference)	Trans-city within province	-89.608	231.118	-0.39	0.698	-543.264	364.048
	Trans-provincial	-2.888	276.767	-0.01	0.992	-546.148	540.371
Hospital type (Traditional Chinese medicine-integrated for reference)	General	-191.100	201.728	-0.95	0.344	-587.067	204.867
	Specialized	-409.379	207.878	-1.97	0.049	-817.418	-1.339
	Traditional Chinese medicine	249.012	256.600	0.97	0.332	-254.662	752.686
Hospital level (Primary for reference)	Secondary	182.541	170.845	1.07	0.286	-152.808	517.890
	Tertiary	532.648	161.920	3.29	0.001	214.818	850.478
Frequency of hospital visit (times) (Once for reference)	1~6th	138.922	206.141	0.67	0.501	-265.707	543.551
	More than 6th	977.649	300.891	3.25	0.001	387.037	1568.262
Length of hospital stay (days) (≤30 for reference)	30~60	369.537	117.093	3.16	0.002	139.698	599.376
	60~90	593.824	160.673	3.70	0.000	278.443	909.205
	>90	521.831	155.129	3.36	0.001	217.332	826.330
Diagnosis code (G30.0 for reference)	G30.1	46.331	276.514	0.17	0.867	-496.433	589.095
	G30.8	-502.180	851.332	-0.59	0.555	-2173.242	1168.882
	G30.9	247.687	231.661	1.07	0.285	-207.035	702.408
City type (Prefecture-level city for reference)	Provincial capital	62.551	121.775	0.51	0.608	-176.479	301.581
	Municipality	-275.701	137.160	-2.01	0.045	-544.930	-6.471
Region (Central for reference)	West	245.001	128.052	1.91	0.056	-6.349	496.351
	East	-27.876	160.894	-0.17	0.862	-343.691	287.939

Characteristics		Coef.	Std.Err.	t	P>t	[95% Conf. Interval]	
Year (2010 for reference)	2013	-881.276	690.633	-1.28	0.202	-2236.906	474.354
	2014	-644.835	677.843	-0.95	0.342	-1975.360	685.689
	2015	-1027.121	679.181	-1.51	0.131	-2360.271	306.029
	2016	-1145.589	677.103	-1.69	0.091	-2474.660	183.481
_cons		808.272	836.656	0.97	0.334	-833.983	2450.527

Note:  $R^2 = 0.1998$  in a quantile regression model that was adjusted for use of CHM, sex, age group, insurance type, settlement type, hospital type, hospital level, frequency of hospital visit, length of hospital stay, diagnosis code, city type, region, year. baseline represents the inpatient cost for a 60 to 65 years old male who did not use any CHM with Urban Resident Basic Medical Insurance admitted to a trans-provincial, traditional Chinese medicine-integrated, specialized and primary hospital only once within 30 days' hospital stay in the prefecture-level and central region city in the year of 2010. CHM: Chinese herbal medicine; UEBMI: Urban Employee Basic Medical Insurance; URBMI: Urban Resident Basic Medical Insurance.